Jiangsu Hengrui Medicine Co., Ltd
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of SHR-1802 in Patients With Failure of Standard Treatment for Advanced Malignant Tumours
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04414150
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 185
- Registration Number
- NCT04409223
- Locations
- 🇨🇳
307 Hospital of PLA, Beijing, China
A Clinical Study of Remimazolam Tosilate in Patients Undergoing Bronchoscopy
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 330
- Registration Number
- NCT04400201
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, China
A Study of Fluzoparib (SHR-3162) and Temozolomide With or Without SHR-1316 in Treating Patients With Replapsed Small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2023-02-13
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT04400188
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Bioequivalence Study of Famitinib Malate on Healthy Chinese Volunteers
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT04400123
- Locations
- 🇨🇳
Xuanwu Hospital Beijing, Capital Medical University, Beijing, Beijing, China
A Bioavailability Study of SHR1459 on Healthy Chinese Volunteers
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04395053
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients
- First Posted Date
- 2020-05-18
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT04390984
- Locations
- 🇨🇳
Sun Yat-Sen Univercity Cancer Center, Guangzhou, Guangdong, China
Efficacy and Safety of SHR3824 in Combination With Metformin in Subjects With Type 2 Diabetes
- First Posted Date
- 2020-05-15
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT04390295
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat - sen University, Guangzhou, Guangdong, China
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Adults
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 201
- Registration Number
- NCT04383418
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
Apatinib and Etoposide Capsule Versus Apatinib in Patients With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2020-05-12
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT04383977
© Copyright 2024. All Rights Reserved by MedPath